Original article for Clinical Infectious Diseases

Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic

Yasuhito Suzuki¹, Yoko Shibata¹, Hiroyuki Minemura¹, Takefumi Nikaido^{1,2}, Yoshinori Tanino¹, Atsuro Fukuhara^{1,9}, Ryuzo Kanno³, Hiroyuki Saito⁴, Shuzo Suzuki⁴, Taeko Ishii⁵, Yayoi Inokoshi⁵, Eiichiro Sando⁶, Hirofumi Sakuma⁷, Tatsuho Kobayashi⁸, Hiroaki Kume⁹, Masahiro Kamimoto¹⁰, Hideko Aoki¹¹, Akira Takama¹², Takamichi Kamiyama¹³, Masaru Nakayama¹⁴, Kiyoshi Saito¹⁵, Koichi Tanigawa¹⁶, Masahiko Sato¹⁷, Toshiyuki Kanbe¹⁸, Norio Kanzaki¹⁹, Teruhisa Azuma²⁰, Keiji Sakamoto²¹, Yuichi Nakamura²¹, Hiroshi Otani²², Mitsuru Waragai²³, Shinsaku Maeda²⁴, Tokiya Ishida²⁵, Keishi Sugino²⁶, Yasuhiko Tsukada²⁷, Ryuki Yamada¹, Riko Sato¹, Takumi Omuna¹, Hikaru Tomita¹, Mikako Saito¹, Natsumi Watanabe¹, Mami Rikimaru¹, Takaya Kawamata¹, Takashi Umeda¹, Julia Morimoto¹, Ryuichi Togawa¹, Yuki Sato¹, Junpei Saito¹, Kenya Kanazawa¹, Ken Iseki²⁷

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

¹Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan; ²Department of Pulmonary Medicine, Ohara General Hospital, Fukushima, Japan; ³Department of Thoracic Surgery, Fukushima Red Cross Hospital, Fukushima, Japan; ⁴Department of Internal Medicine, Fujita General Hospital, Fukushima, Japan; ⁵Department of Pulmonary Medicine, Saiseikai Fukushima General Hospital, Fukushima, Japan; ⁶Department of General Internal Medicine and Clinical Infectious Diseases, Fukushima Medical University, Fukushima, Japan; ⁷Department of Internal Medicine, Saiseikai Kawamata Hospital, Fukushima, Japan; ⁸Department of Emergency and Critical Care Medicine, Aizu Chuo Hospital, Fukushima, Japan; ⁹Department of Infectious Disease and Pulmonary Medicine, Aizu Medical Center, Fukushima Medical University, Fukushima, Japan; ¹⁰Department of Internal Medicine, Takeda General Hospital, Fukushima, Japan; ¹¹Department of Pediatric Medicine, Bange Kousei General Hospital, Fukushima, Japan; ¹²Department of Surgery, Yurin Hospital, Fukushima, Japan; ¹³Department of Pediatric Surgery, Iwaki City Medical Center, Fukushima, Japan; ¹⁴Department of Internal Medicine, Kashima Hospital, Fukushima, Japan; ¹⁵Department of Neurosurgery, Fukushima Rosai Hospital, Fukushima, Japan; ¹⁶Department of Emergency and Critical Care Medicine, Futaba Medical Center, Fukushima, Japan; ¹⁷Department of Internal Medicine, Soma General

Hospital, Fukushima, Japan; ¹⁸Department of Pulmonary Medicine, Minami-Soma Municipal General Hospital, Fukushima, Japan; ¹⁹Department of Surgery, Onahama Chuo Clinic, Fukushima, Japan; ²⁰Department of General Medicine, Shirakawa Satellite for Teaching and Research, Fukushima Medical University, Fukushima, Japan; ²¹Department of Cardiology and Vascular Medicine, Hoshi General Hospital, Fukushima, Japan; ²²Department of Internal Medicine, Iwase General Hospital; ²³Department of Surgery, Southern TOHOKU General Hospital, Fukushima, Japan; ²⁴Department of Pulmonary Medicine, Jusendo General Hospital, Fukushima, Japan; ²⁵Department of Emergency and Critical Care Medicine, Ohta Nishinouchi Hospital, Fukushima, Japan; ²⁶Department of Respiratory Medicine, Tsuboi Hospital, Fukushima, Japan; ²⁷Department of Emergency and Critical Care Medicine, Fukushima Medical University, Fukushima, Japan

Word counts of the abstract and the text: 213 and 2918, respectively.

Tables: 5, Figures: 1

Correspondence:

All correspondence should be addressed to Yoko Shibata, MD, PhD.

Address: Department of Pulmonary Medicine, Fukushima Medical University, School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima Prefecture, 960-1295, Japan.

Tel: +81-24-547-1360

Fax: +81-24-548-9366

Email: shibatay@fmu.ac.jp

Author contributions:

Conception and design: Yasuhito Suzuki and Yoko Shibata. Analysis and drafting the manuscript: Yasuhito Suzuki and Yoko Shibata. Data curation: all authors. Final approval of the manuscript: Yasuhito Suzuki and Yoko Shibata.

Running title

Casirivimab-imdevimab for Delta variant

Summary

This real-world retrospective study demonstrates the contribution of treatment with casirivimab-imdevimab to the prevention of deterioration in patients with mild-to-

moderate coronavirus disease 2019 (COVID-19) even during the Delta variant
pandemic.

Footnote page

Conflict of Interest

Yoko Shibata and Hiroyuki Minemura received lecture fees and research grants from Chugai Pharmaceutical Co., Ltd. The other authors report no conflicts of interest related to this study.

Funding

This study received no specific grant from any funding agency.

Abstract (213 words)

Background: Mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may reduce the efficacy of neutralizing monoclonal antibody therapy against coronavirus disease 2019 (COVID-19). We here evaluated the efficacy of casirivimab-imdevimab in patients with mild-to-moderate COVID-19 during the Delta variant surge in Fukushima Prefecture, Japan.

Methods: We enrolled 949 patients with mild-to-moderate COVID-19 who were admitted to hospital between July 24, 2021 and September 30, 2021. Clinical deterioration after admission was compared between casirivimab-imdevimab users (n = 314) and non-users (n = 635).

Results: The casirivimab-imdevimab users were older ($P < 0.0001$), had higher body temperature ($\geq 38^{\circ}\text{C}$) ($P < 0.0001$) and greater rates of history of cigarette smoking ($P = 0.0068$), hypertension ($P = 0.0004$), obesity ($P < 0.0001$), and dyslipidemia ($P < 0.0001$) than the non-users. Multivariate logistic regression analysis demonstrated that receiving casirivimab-imdevimab was an independent factor for preventing deterioration (odds ratio 0.448; 95% confidence interval 0.263–0.763; $P = 0.0023$). Furthermore, in 222 patients who were selected from each group after matching on the propensity score, deterioration was significantly lower among those receiving

casirivimab-imdevimab compared to those not receiving casirivimab-imdevimab (7.66% vs 14.0%; $p = 0.021$).

Conclusion: This real-world study demonstrates that casirivimab-imdevimab contributes to the prevention of deterioration in COVID-19 patients after hospitalization during a Delta variant surge.

Keywords

casirivimab-imdevimab, COVID-19, SARS-CoV-2, Delta variant, real-world effectiveness

Abbreviations

BMI: body mass index

CI: confidence interval

CKD: chronic kidney disease

COVID-19: coronavirus disease 2019

CRP: C-reactive protein

ECMO: extracorporeal membrane oxygenation

IQR: interquartile range

LDH: lactate dehydrogenase

OR: odds ratio

PCR: polymerase chain reaction

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

1. Introduction

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is continuing to spread around the world. Vaccines against SARS-CoV-2 have reduced infection and mortality and being widespread all over the world. Newly emerging variants have mutations in the spike protein of SARS-CoV-2 and show high infectivity [1]. Many neutralizing antibodies and vaccines against SARS-CoV-2 target this spike protein. Therefore, spike protein mutations may diminish their effectiveness [2]. Indeed, cases of the B.1.617.2 (Delta) variant, which possesses high transmissibility, spread throughout Japan from July to October 2021 [3].

Neutralizing monoclonal antibody therapy has been authorized by the United States Food and Drug Administration for treatment of high-risk patients with mild-to-moderate COVID-19 [4, 5]. Casirivimab-imdevimab is two recombinant human IgG1 monoclonal antibodies, known as REGN-COV2, that are used for the treatment of COVID-19 [5]. These antibodies are derived from humanized mice and the sera of patients recovering from COVID-19, and bind non-competitively to non-overlapping epitopes of the spike protein receptor-binding domain of SARS-CoV-2, thereby preventing viral attachment and cell entry [6, 7]. To date, a few investigations have

reported the real-world effect of casirivimab-imdevimab as outpatient treatment for mild-to-moderate COVID-19 cases with high-risk aggravations [8-10]. These studies demonstrated that use of casirivimab-imdevimab decreased hospitalization and mortality rates. However, it remains unclear whether casirivimab-imdevimab is also effective for treatment of the SARS-CoV-2 Delta variant.

Starting in March 2020, we have been gathering the medical information of patients with COVID-19, who were hospitalized in 26 medical institutes in Fukushima Prefecture, in our electronic database. A total of 4,568 COVID-19 patients were registered by the end of September 2021. Even in Fukushima Prefecture, the Delta variant was widely spread, and from July to September 2021, the most frequently detected variant of SARS-CoV-2 was the Delta variant [11]. Furthermore, starting in July 2021, casirivimab-imdevimab has been approved in Japan for treating mild-to-moderate COVID-19 patients who are at high-risk of deterioration. Hence, our database was available to evaluate the clinical efficacy of casirivimab-imdevimab against SARS-CoV-2 in the real-world setting.

To the best of our knowledge, the present study is the first real-world retrospective study to evaluate the efficacy of casirivimab-imdevimab for cases of mild-to-moderate COVID-19 caused by the Delta variant of SARS-CoV-2. We compared the

clinical outcomes of patients with mild-to-moderate COVID-19 treated with casirivimab-imdevimab therapy to those who underwent alternative treatments.

2. Methods

2.1. Study design and population

This retrospective cohort study was conducted using an electronic database and enrolled 4,568 COVID-19 patients (as of the end of September 2021) who were admitted to 26 hospitals in Fukushima Prefecture. Those hospitals participated in the web conferences organized by the Department of Pulmonary Medicine, Fukushima Medical University. Among the 4,568 patients, the data of 790 were excluded, because those patients had severe COVID-19, treatment for which casirivimab-imdevimab is not eligible. Among the remaining 3,778 patients, we excluded 2,829 as they were admitted before casirivimab-imdevimab became available on July 24, 2021 in Fukushima prefecture. Finally, we analyzed the data of 949 patients. The subjects in the current study included patients who had been vaccinated against SARS-CoV-2. The clinical characteristics, including comorbidities, examination results, medications, as well as clinical course and outcomes of the subjects, were obtained from the electronic database of each hospital. In the current study, the subjects who received

the vaccine twice were categorized as "received vaccination".

The diagnosis of COVID-19 was made by positive results for SARS-CoV-2 polymerase chain reaction (PCR) on nasopharyngeal swab or saliva samples. Assessment of COVID-19 severity was performed according to the definition issued by the Japanese Ministry of Health, Labor and Welfare: mild, patients without pneumonia or respiratory failure; moderate-1, patients with pneumonia but without respiratory failure; moderate-2, patients with pneumonia and respiratory failure (percutaneous oxygen saturation < 94% on room air) but do not require mechanical ventilation/extracorporeal membrane oxygenation (ECMO); or severe, patients with pneumonia and respiratory failure who require mechanical ventilation/ECMO [12, 13].

Retrospectively, the patients were divided into two groups: (1) those treated with casirivimab-imdevimab; and (2) those not treated with casirivimab-imdevimab (controls). If a patient's condition deteriorated during the clinical course after the administration of casirivimab-imdevimab, other therapies for COVID-19, including antiviral drugs or immunomodulatory agents (remdesivir, favipiravir, corticosteroid, baricitinib, or tocilizumab), were prescribed and administered at the attending doctor's discretion.

2.2. Patient Eligibility Criteria

The inclusion criteria for treatment with casirivimab-imdevimab were guided by those for the COV-2067 trial [5], and the recommendation of the Japanese Ministry of Health, Labor and Welfare [12]. In particular, patients who were aged ≥ 18 years were eligible for casirivimab-imdevimab treatment if they had symptoms of COVID-19 (e.g., cough, sore throat, fever, and constitutional symptoms), were within 7 days of symptom onset, and had at least one of the following criteria for high risk aggravation: an age of ≥ 50 years, body mass index (BMI) of ≥ 30 kg/m², use of immunosuppressive medication, immunocompromised status, and presence of hypertension, cardiovascular disease, chronic lung disease, chronic kidney disease (CKD), diabetes mellitus and/or chronic liver disease.

2.3. Outcomes of interest

The primary outcomes of interest were any clinical deterioration, need for mechanical ventilation/ECMO, and death after initiation of casirivimab-imdevimab. The secondary outcomes included factors that influenced clinical deterioration.

The definition of clinical deterioration in the present study was a worsened respiratory condition requiring respiratory therapy (use of inhalation oxygen,

mechanical ventilation, or ECMO) or the initiation of other medications for COVID-19 (remdesivir, favipiravir, corticosteroid, baricitinib, or tocilizumab) after the first day of hospitalization.

2.4. Statistical analyses

Continuous variables are shown as median with interquartile range (IQR) and categorical variables are shown as numbers and percentages. Comparisons between groups for the continuous variables and categorical variables were performed using Mann-Whitney U test and chi-square test, respectively. Age was reclassified as a categorical variable according to the cutoff values obtained from the receiver operating characteristic (ROC) curve of univariate logistic regression analysis for predicting deterioration during hospitalization. Based on the ROC curve and Youden index analysis, we determined that the best cut-off age was 43 (sensitivity 73.6%, specificity 56.4%). Among the comorbidities, those with a prevalence of $\geq 2\%$ were applied to the analyses. The variables that had statistically significant differences between the casirivimab-imdevimab users and non-users were used to identify independent risk factors for predicting deterioration a day or later after admission via multivariate logistic regression analysis. Adjusted odds ratios (OR) with 95% confidence interval (CI) were

calculated.

In addition, we compared the risk of exacerbation between the casirivimab-imdevimab users and non-users using the DOAT score. The DOAT score is a simple predictive model that we established and reported in a previous study [14]. It consists of three items: 1) having the comorbidity of diabetes or obesity, 2) being aged ≥ 40 years, and 3) having high body temperature ($\geq 38^{\circ}\text{C}$). The DOAT score range is 0–3 points, and a high DOAT score (optimal cutoff point is 2) denotes a higher possibility of deterioration in non-elderly COVID-19 patients who do not have respiratory failure on admission.

Furthermore, we used the propensity score technique to match casirivimab-imdevimab users and non-users. The propensity score method selected covariates that may influence casirivimab-imdevimab administration [15]. Logistic regression was performed to estimate the propensity of initiating casirivimab-imdevimab users versus non-user, including 14 confounders that are related to deterioration risk (age, sex, cigarette smoking, high body temperature, percutaneous oxygen saturation, severity, receiving the vaccine, hypertension, obesity, diabetes, dyslipidemia, respiratory diseases, CKD, and collagen vascular disease). We then matched subjects on the logit of the propensity score using a caliper of width equal to 0.2 of the standard deviation

of logit of the propensity score [16]. We excluded patients with moderate-2 and severe status from the analyses, because we were unable to match them with control patients.

All statistical analyses were performed using JMP 13 (SAS Institute Inc, Cary NC) and EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan). A two-tailed p-value of < 0.05 was considered statistically significant. Cases with missing data were not excluded from the analyses.

2.5. Ethics statement

The need for informed consent was waived because the study is retrospective. This study was approved by the Ethics Committee of Fukushima Medical University (approval number 2020-118, approved on August 3, 2020, updated September 01, 2021).

3. Results

3.1. Characteristics of participants

The patient selection flowchart is shown in Figure 1. Among the 949 COVID-19 patients enrolled in the current study, 314 were administered casirivimab-imdevimab. The differences in characteristics between the casirivimab-imdevimab

users and non-users are demonstrated in Table 1. The casirivimab-imdevimab users were significantly older ($P < 0.0001$), and had higher body temperature ($\geq 38^{\circ}\text{C}$) ($P < 0.0001$) and a higher history of cigarette smoking ($P = 0.0068$) compared to the non-users. The disease severity was significantly higher in the non-users compared to the casirivimab-imdevimab users ($P = 0.0003$). Regarding comorbidities, in the casirivimab-imdevimab users, there was a significantly higher prevalence of hypertension ($P = 0.0004$), obesity ($P < 0.0001$), and dyslipidemia ($P < 0.0001$). There were no significant differences in sex, diabetes, chronic respiratory diseases, malignancies, cardiac disease, CKD, and being vaccinated between the two groups. With regard to physical and laboratory examinations, ferritin levels ($P = 0.0102$) and DOAT score ($P < 0.0001$) were significantly higher in the casirivimab-imdevimab users than in the non-users. On the other hand, percutaneous oxygen saturation level, white blood cells, neutrophil percentage, lymphocyte percentage, C-reactive protein (CRP), lactate dehydrogenase (LDH), and D-dimer did not significantly differ between the groups.

3.2. Clinical outcomes of treatment with casirivimab-imdevimab

Among all patients analyzed in the present study, 104 experienced

deterioration a day after admission or later. The primary endpoints of the rates of clinical deterioration, need for mechanical ventilation/ECMO, and death for the total population were 11.0%, 0.53%, and 0.63%, respectively. One casirivimab-imdevimab user with moderate-1 status died, and there were no significant differences regarding rates of clinical deterioration, need for mechanical ventilation/ECMO and death between the two groups (Table 2).

3.3. Independent risk factors of deterioration after hospitalization

The results of multivariate logistic regression analysis of COVID-19 deterioration during hospitalization are shown in Table 3. According to this analysis, age ≥ 43 years ($P = 0.0004$), being unvaccinated ($P = 0.0002$), not receiving casirivimab-imdevimab ($P = 0.0023$), and dyslipidemia ($P = 0.0290$) were independent risk factors related to the clinical deterioration of COVID-19 (Table 3).

3.4. The clinical deterioration rate between two groups after propensity score matching

Using the propensity score matching method, 222 patients were selected from each group. The baseline clinical characteristics after adjusting for propensity score

are summarized in Table 4. There were no significant differences between the two groups, except for the percentage of neutrophils in blood test. The clinical deterioration rate was significantly lower in the casirivimab-imdevimab users compared to the non-users (7.66% vs 14.0%; $p = 0.021$). None of the 222 patients in both groups required mechanical ventilation/ECMO. One casirivimab-imdevimab user died, but there was no significant difference regarding the death rate between the two groups (Table 5).

4. Discussion

In the present study, we investigated the effectiveness of casirivimab-imdevimab utilizing real-world data from 949 COVID-19 patients who had been admitted to hospitals in Fukushima Prefecture between July 2021 and September 2021 during the Delta variant pandemic. The patients taking casirivimab-imdevimab were older and had more frequent comorbidities such as hypertension, obesity, and dyslipidemia compared to those who were not taking casirivimab-imdevimab. These differences may have been caused by the eligibility criteria of treatment with casirivimab-imdevimab. Thus, it is natural that the DOAT score [14], which is a predictive score of disease progression in COVID-19 patients with mild-to-moderate-1 severity, was higher in the casirivimab-imdevimab users than in the non-users. On the

other hand, the disease severity was significantly higher in the non-users. There was no significant difference in clinical outcomes between the two groups in the analysis of data before adjustment for differences in patient characteristics. However, because there were several significant differences in clinical characteristics between the two groups, we performed a multivariate logistic regression analysis that included the confounding factors as explanatory variables. The analysis results demonstrated that not receiving casirivimab-imdevimab was an independent risk factor for deterioration of COVID-19. Furthermore, a propensity score matching analysis for mild-to-moderate patients revealed the effectiveness of casirivimab-imdevimab hidden behind the confounding factors. These results are consistent with a previous study that showed casirivimab-imdevimab treatment to be associated with a significantly lower rate of hospitalization among high-risk patients with mild-to-moderate COVID-19 [9].

In the current study, information on SARS-CoV-2 variants in individual cases was unknown. However, according to a survey performed by the Fukushima Prefectural Institute of Public Health, the proportion of Delta variant cases reached 70% by the end of July 2021 in Fukushima Prefecture, and exceeded 90% after the middle of the following month [11] . Therefore, it is reasonable to consider that almost all cases analyzed in the present study were Delta variant cases. Thus, the results of

present study indicate that casirivimab-imdevimab is effective against the SARS-CoV-2 Delta variant.

The Delta variant, which was first detected in India in 2020, has attained global dominance with a higher transmissibility and immune evasion [17]. In vitro and in vivo, casirivimab-imdevimab retains neutralization potency against SARS-CoV-2 variants, including B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), B.1.429 (Epsilon), and P.1 (Gamma), and may prevent the selection of resistant variants [18, 19]. According to a previous report by Wilhelm A et al., in which a cell culture-based neutralization assay focusing on the Delta variant was performed, the Delta variant was resistant to imdevimab alone; however, they hypothesized that this might be circumvented by combination treatment with casirivimab [20]. Recently, Kumar et al. reported in their single-center prospective cohort study in India that the use of casirivimab-imdevimab for treating high-risk SARS-CoV-2 patients infected with the Delta variant demonstrated faster improvement of symptoms along with reduced viral loads compared with patients who had been administered remdesivir [21]. Although their results support those of the present study, the details regarding the disease severity and the deterioration rate in the patients taking casirivimab-imdevimab in their study are unknown. Taking our real-world results together with those from Kumar et al., we

believe that casirivimab-imdevimab is suggested to be effective for the treatment of the SARS-CoV-2 Delta variant.

The efficacy of SARS-CoV-2 vaccine against the Delta variant was also revealed by multivariate logistic regression analysis in the present study (Table 3). Full vaccination significantly prevented deterioration in the mild-to-moderate COVID-19 patients (OR 0.147, 95% CI 0.042–0.515). Simultaneously, our study showed that casirivimab-imdevimab contributes to the prevention of deterioration (OR 0.448, 95% CI 0.263–0.763), regardless of having received a SARS-CoV-2 vaccine. The effectiveness of SARS-CoV-2 vaccination remains unclear for some variants. The current vaccines have been effective against some variants, such as the B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta) variants [22, 23], but have reportedly been less effective against the B.1.621 (Mu) variant [24]. Although further investigation is still required, combination use of SARS-CoV-2 vaccine and casirivimab-imdevimab may synergistically reduce disease progression and mortality of patients with COVID-19 caused by variants.

The strength of the current study is that its results are considered to be generalizable because the population was comprised of inpatients at major hospitals in Fukushima Prefecture that handle COVID-19 inpatient treatment. During the study

period, in Fukushima Prefecture, which has a total population of approximately 2 million people, there were 4,155 people infected with COVID-19 [25] , and 23% of those patients were registered in the database of the current study.

There are several limitations to the present study. First, this was an observational and retrospective study, and does not show evidence comparable to a randomized clinical trial. Although we carefully adjusted clinical outcomes for various potential confounding factors, potential bias due to the study design is inevitable. Second, in some subjects, the precise information about the number of days between COVID-19 symptom onset and the administration of casirivimab-imdevimab, and the day of deterioration were not included in our electronic database. Therefore, there may be some influence on the clinical outcomes. Third, the adverse effects of casirivimab-imdevimab were not evaluated in detail. However, according to previous studies, adverse effects were uncommon and mild [5, 10]. Fourth, information regarding which SARS-CoV-2 variant each individual had was not included in the current study. However, as we mentioned above, almost all patients were considered to be infected with the Delta variant during the study period in most of Japan [3], including Fukushima Prefecture [11]. Fifth, regarding the vaccinated patients information on how many days before disease onset they completed SARS-CoV-2 vaccination was not available.

Although the vast majority of healthy individuals respond to the vaccines and obtain full efficacy against SARS-CoV-2 at least 7 days after second vaccination [26], some of our subjects may have been infected with the virus shortly after their second vaccination. The period between the second vaccination and onset of COVID-19 may have influenced some of the results obtained in the present study. However, this effect seems to be minor, because we demonstrated the effectiveness of casirivimab-imdevimab regardless of vaccination in our multivariate logistic regression analysis (Table 3). Sixth, as the study population was almost entirely Japanese, different results may be obtained with different ethnic population. Further study is needed to validate these findings in other ethnic populations.

5. Conclusion

This real-world retrospective study of high-risk patients with mild-to-moderate COVID-19 demonstrated a low rate of clinical deterioration after treatment with casirivimab-imdevimab, regardless of whether the patients had received a SARS-CoV-2 vaccine. Aggressive use of casirivimab-imdevimab should be considered to prevent deterioration in high-risk patients with mild-to-moderate COVID-19.

Acknowledgements

We thank the Scientific English Editing Section of Fukushima Medical University for their fruitful discussion and linguistic assistance in proofreading the manuscript.

Figure legends

Figure 1. Flowchart of patients' recruitment in this study

Among a total of 4,568 registered COVID-19 patients in our electronic database, 949 were selected for the present study.

References

1. Korber B, Fischer WM, Gnanakaran S, et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. *Cell* **2020**; 182(4): 812-27.e19.
2. Hu J, Peng P, Wang K, et al. Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies. *Cellular & molecular immunology* **2021**; 18(4): 1061-3.
3. Ito K, Piantham C, Nishiura H. Predicted dominance of variant Delta of SARS-CoV-2 before Tokyo Olympic Games, Japan, July 2021. *Euro surveillance : bulletin European sur les maladies transmissibles = European communicable disease bulletin* **2021**; 26(27).
4. Gottlieb RL, Nirula A, Chen P, et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. *Jama* **2021**; 325(7): 632-44.
5. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. *The New England journal of medicine* **2021**; 384(3): 238-51.

6. Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. *Acta pharmacologica Sinica* **2020**; 41(9): 1141-9.
7. Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. *Nature reviews Immunology* **2021**; 21(6): 382-93.
8. Ganesh R, Philpot LM, Bierle DM, et al. Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019. *The Journal of infectious diseases* **2021**; 224(8): 1278-86.
9. Razonable RR, Pawlowski C, O'Horo JC, et al. Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. *EClinicalMedicine* **2021**; 40: 101102.
10. Verderese JP, Stepanova M, Lam B, et al. Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate COVID-19: A Real-World Experience. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* **2021**.
11. The_official_website_of_Fukushima_Prefecture. The variant of COVID-19 in Fukushima from July to September 2021 (in Japanese). Available at: <https://www.pref.fukushima.lg.jp/site/covid19-portal/variant.html>. Accessed October 10, 2021.
12. Japan_Ministry_of_Health_Labor_and_Welfare. Clinical Management of patients with COVID-19: A guide for front-line healthcare workers (in Japanese). Available at: https://www.niph.go.jp/h-crisis/wp-content/uploads/2020/07/20200706103735_content_000646531.pdf. Accessed September 16, 2021.
13. Yamamoto A, Wada H, Ichikawa Y, et al. Evaluation of Biomarkers of Severity in Patients with COVID-19 Infection. *J Clin Med* **2021**; 10(17): 3775.
14. Shibata Y, Minemura H, Suzuki Y, et al. Development and external validation of the DOAT and DOATS scores: simple decision support tools to identify disease progression among nonelderly patients with mild/moderate COVID-19. *medRxiv [Preprint]* December 14, 2021 [cited 2021 Dec 15] Available from: <https://doi.org/10.1101/2021121321267698>.
15. Shiba K, Kawahara T. Using Propensity Scores for Causal Inference: Pitfalls and Tips. *Journal of epidemiology* **2021**; 31(8): 457-63.
16. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. *Pharmaceutical statistics* **2011**; 10(2): 150-61.
17. Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature* **2021**; 596(7871): 276-80.

18. Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. *Science (New York, NY)* **2020**; 369(6506): 1014-8.
19. Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature* **2021**; 593(7857): 130-5.
20. Wilhelm A, Toptan T, Pallas C, et al. Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q. *Viruses* **2021**; 13(9).
21. Kumar VJ, Banu S, Sasikala M, et al. Effectiveness of REGEN-COV antibody cocktail against the B.1.617.2 (delta) variant of SARS-CoV-2: A cohort study. *Journal of internal medicine* **2021**.
22. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *The New England journal of medicine* **2021**; 385(2): 187-9.
23. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *The New England journal of medicine* **2021**; 385(7): 585-94.
24. Uriu K, Kimura I, Shirakawa K, et al. Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum. *The New England journal of medicine* **2021**; 385(25): 2397-9.
25. The_official_website_of_Fukushima_Prefecture. Confirmed cases of COVID-19 in Fukushima (in Japanese). Available at: <https://www.pref.fukushima.lg.jp/sec/21045c/fukushima-hasseijyoukyou0307.html>. Accessed October 30, 2021.
26. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *The New England journal of medicine* **2020**; 383(27): 2603-15.

Table 1. Comparison of baseline clinical characteristics between the casirivimab-imdevimab users and non-users

	All subjects n = 949	Casirivimab-imdevimab users n = 314	Casirivimab-imdevimab non-users n = 635	<i>P</i> value	Missing data
Age, year	46 (30, 56)	51 (43, 59)	41 (25, 54)	< 0.0001	0
Male	532 (56.1%)	192 (61.2%)	340 (53.6%)	0.0739	1
Received vaccination	94 (10.2%)	28 (9.09%)	66 (10.8%)	0.4280	28
Mild /Moderate-1/ Moderate-2/Severe	418/426/73/2	135/168/11/0	283/258/62/2	0.0003	30
History of cigarette smoking	383 (41.9%)	148 (48.1%)	235 (38.7%)	0.0068	34
Body temperature $\geq 38^{\circ}\text{C}$	380 (41.0%)	157 (50.2%)	223 (36.4%)	< 0.0001	23
Diabetes	105 (11.9%)	40 (12.9%)	65 (11.4%)	0.4952	69
Obesity	161 (18.3%)	84 (27.2%)	77 (13.5%)	< 0.0001	68
Hypertension	212 (24.1%)	96 (31.0%)	116 (20.3%)	0.0004	68
Chronic respiratory diseases	57 (6.50%)	26 (8.44%)	31 (5.44%)	0.0848	71
Malignancies	26 (3.00%)	12 (3.90%)	14 (2.46%)	0.2297	71
Dyslipidemia	78 (8.90%)	50 (16.2%)	28 (4.91%)	< 0.0001	71
Cardiac diseases	62 (7.10%)	34 (11.0%)	28 (4.91%)	0.0550	70
Chronic kidney disease	18 (2.05%)	10 (3.24%)	8 (1.40%)	0.0670	70
SpO ₂ , %	97 (96, 98)	97 (96, 98)	97 (96, 98)	0.6494	30
White blood cells, / μL	4500 (3585, 5620)	4410 (3600, 5500)	4500 (3540, 5700)	0.6449	76
Neutrophils, %	64.3 (55.0, 72.0)	64.5 (54.7, 72.0)	64.2 (55.0, 72.0)	0.7084	110
Lymphocyte, %	25.0 (18.1, 31.6)	24.6 (17.8, 31.3)	25.0 (18.4, 31.9)	0.4085	101

CRP, mg/dL	0.90 (0.30, 2.51)	0.93 (0.30, 2.51)	0.88 (0.29, 2.53)	0.8307	77
LDH, IU/L	205 (174, 254)	210 (182, 254)	202 (171, 257)	0.1542	199
D-dimer, µg/mL	0.50 (0.27, 0.80)	0.50 (0.30, 0.70)	0.50 (0.25, 0.80)	0.4919	193
Ferritin, ng/mL	181 (83.5, 342)	207 (107, 375)	157 (75.6, 320)	0.0102	433
DOAT score	1 (1, 2)	2 (1, 2)	1 (1, 2)	< 0.0001	78

Continuous variables are shown as medians with interquartile range, and categorical variables are shown as numbers with percentages.

Definition of abbreviations: CRP, C-reactive protein; LDH, lactate dehydrogenase; DOAT score, a predictive model for clinical deterioration in mild-to-moderate COVID-19 patients using three items, having diabetes or obesity, age ≥ 40 years, and high body temperature ($\geq 38^{\circ}\text{C}$) (Details are described in the manuscript), SpO₂, percutaneous oxygen saturation.

Table 2. Comparison of the clinical outcomes between the casirivimab-imdevimab users and non-users

	All subjects n = 949	Casirivimab- imdevimab users n = 314	Casirivimab- imdevimab non-users n = 635	<i>P</i> value	Missing data
Deterioration during hospitalization	104 (11.0%)	34 (10.8%)	70 (11.0%)	0.6179	86
Exacerbation requiring for mechanical ventilation/ECMO	5 (0.53%)	0 (0%)	5 (0.79%)	0.1149	0
Death due to COVID-19	6 (0.63%)	1 (0.32%)	5 (0.79%)	0.3911	0

Definition of abbreviation: ECMO, extracorporeal membrane oxygenation.

Table 3. Multivariate logistic regression analysis of deterioration among patients with COVID-19 after hospitalization

	β regression coefficient	OR	95% CI	<i>P</i> value
Age $\geq$ 43 years-old	0.466	2.543	1.491–4.337	0.0004
History of cigarette smoking	-0.088	0.839	0.529–1.328	0.4230
Severity, per 1 grade-increase	-0.0158	0.984	0.678–1.427	0.9334
Received vaccination	-0.9565	0.147	0.042–0.515	0.0002
Casirivimab-imdevimab	-0.4006	0.448	0.263–0.763	0.0023
Dyslipidemia	0.4074	2.258	1.113–4.582	0.0290
Obesity	0.2572	1.672	0.963–2.903	0.0739
Hypertension	0.0897	1.196	0.685–2.087	0.5299
Cardiovascular disease	0.2948	1.803	0.844–3.853	0.1390
Chronic kidney disease	0.5339	2.909	0.709–11.929	0.1550
Chronic respiratory disease	0.0129	1.026	0.413–2.546	0.9557
Body temperature $\geq$ 38°C	0.0196	1.039	0.650–1.663	0.8704

COVID-19 severity grade: mild, subjects without pneumonia or respiratory failure; moderate-1, subjects with pneumonia but without having respiratory failure; moderate-2, subjects with pneumonia and respiratory failure (oxygen saturation < 94% on room air) but who do not require mechanical ventilation/extracorporeal membrane oxygenation (ECMO); and severe, subjects with pneumonia and respiratory failure who require mechanical ventilation/ECMO

Definition of abbreviations: CI, confidence interval; OR, odds ratio.

Table 4. Comparison of baseline clinical characteristics between the casirivimab-imdevimab users and non-users after adjustment with propensity score

	Casirivimab-imdevimab users n = 222	Casirivimab-imdevimab non-users n = 222	<i>P</i>
Age, year	50 (39, 57)	50 (41, 57)	0.563
Male	133 (59.9%)	124 (55.9%)	0.442
Received vaccination	22 (9.90%)	23 (10.4%)	1.000
Mild/Moderate-1/Moderate-2/Severe	96/126/0/0	93/129/0/0	0.848
History of cigarette smoking	103 (46.4%)	104 (46.8%)	0.784
Body temperature $\geq 38^{\circ}\text{C}$	96 (43.2%)	92 (41.4%)	0.773
Diabetes	28 (12.6%)	31 (14.0%)	0.780
Obesity	51 (23.0%)	49 (22.1%)	0.910
Hypertension	54 (24.3%)	57 (25.7%)	0.827
Chronic respiratory diseases	16 (7.20%)	18 (8.1%)	0.859
Malignancies	5 (2.30%)	5 (2.3%)	1.000
Dyslipidemia	19 (8.60%)	16 (7.2%)	0.725
Cardiac diseases	17 (7.70%)	15 (6.8%)	0.855
Chronic kidney disease	4 (1.89%)	3 (1.4%)	1.000
SpO ₂ , %	97 (96, 98)	97 (96, 98)	0.854
White blood cells, / μL	4400 (3500, 5300)	4600 (3600, 5700)	0.150
Neutrophil, %	63.0 (54.2, 72.0)	66.3 (57.9, 73.5)	0.033
Lymphocyte, %	24.8 (18.3, 31.0)	23.4 (17.9, 31.1)	0.412

CRP, mg/dL	0.70 (0.25, 2.48)	0.97 (0.38, 2.39)	0.218
LDH, IU/L	208 (179, 242)	208 (173, 260)	0.529
D-dimer, µg/mL	0.47 (0.24, 0.66)	0.47 (0.20, 0.80)	0.455
Ferritin, ng/mL	178 (96.0, 348)	211 (81.4, 377)	0.696

Continuous variables are shown as medians with interquartile range, and categorical variables are shown as numbers with percentages.

Definition of abbreviations: CRP, C-reactive protein; LDH, lactate dehydrogenase; SpO₂, percutaneous oxygen saturation.

Table 5. Comparison of the clinical outcomes between the casirivimab-imdevimab users and non-users after adjustment with propensity score

	Casirivimab- imdevimab users n = 222	Casirivimab- imdevimab non-users n = 222	<i>P</i> value
Deterioration during hospitalization	17 (7.66%)	31 (14.0%)	0.021
Exacerbation requiring for mechanical ventilation/ECMO	0 (0%)	0 (0%)	N/A
Death due to COVID-19	1 (0.45%)	0 (0%)	1.000

Definition of abbreviations: ECMO, extracorporeal membrane oxygenation; N/A, not applicable

A total of 4,568 registered patients in the database of this study by Sep. 30, 2021

790 patients from three hospitals that treat severe or critical COVID-19 cases

3,778 patients from 23 hospitals that treat mild and moderate COVID-19 cases

2,829 patients who were admitted to hospital before July 24, 2021

949 patients who were admitted to hospital between July 24 and Sep. 30, 2021